Josh Blacher
About Josh Blacher
Josh Blacher Interim Chief Financial Officer
Josh Blacher currently serves as the Interim Chief Financial Officer. With a career spanning over 20 years, he has held pivotal roles in leading private and Nasdaq-listed companies. His domain expertise lies predominantly in the life sciences and biotech sectors. Through these roles, he has developed significant proficiency in financial strategy, pioneering new financial models, and establishing global initiatives.
Josh Blacher Education and Academic Background
Josh Blacher earned a Bachelor of Arts in Economics from Yeshiva University, laying a strong foundation in economic theories and applications. Furthering his education, he holds an MBA in Finance from Columbia Business School, equipping him with advanced knowledge and skills in finance. These academic accomplishments have been instrumental in shaping his successful career in financial leadership.
Josh Blacher Finance Experience in Corporate Development
Josh Blacher's background includes influential roles in corporate development. He has worked for Columbus Circle Capital and Teva Pharmaceuticals, where he honed his skills in strategic growth and corporate management. His experience in these positions has provided him with a robust understanding of the intricacies involved in corporate finance and development within the life sciences and biotech sectors.
Josh Blacher Investment Management Roles
Josh Blacher has also contributed significantly to the field of investment management, with roles at Deutsche Asset Management and Morgan Stanley. In these positions, he gained extensive experience in managing investments, understanding market dynamics, and assessing financial risks. His deep-rooted knowledge in investment management has played a crucial part in shaping his career trajectory and expertise.
Josh Blacher Leadership in Life Science and Biotech Companies
Throughout his career, Josh Blacher has held substantial leadership positions in various life science and biotech companies. These include roles as Chief Financial Officer and Chief Business Officer for RNA Disease Diagnostics, InMed Pharmaceuticals, Therapix Biosciences, and Galmed Pharmaceuticals. His leadership in these companies encompasses building finance functions, raising profitability, and executing high-impact deals such as IPOs, follow-on offerings, M&A, licensing, and partnerships.